October 4, 2022
A high-profile NFL injury has put the spotlight back on football’s persistent concussions, which are linked to head trauma and a variety of long-lasting symptoms, and […]
October 4, 2022
Too much sleep and time in bed (TIB) may raise the risk of developing dementia and Alzheimer’s disease (AD), new research suggests. Results from a population-based […]
September 30, 2022
The Medicare and Medicaid programs spent more than $18 billion over 3 years on medications for which there was no proof of a significant clinical benefit, […]
September 29, 2022
The US Food and Drug Administration (FDA) has approved sodium phenylbutyrate/taurursodiol (Relyvrio, Amylyx Pharmaceuticals), a novel drug to treat amyotrophic lateral sclerosis (ALS). The approval was […]
September 28, 2022
Lecanemab (Eisai/Biogen), an investigational amyloid-clearing monoclonal antibody, reduced cognitive decline by 27% compared to placebo and decreased amyloid levels in the brain of adults enrolled in […]
September 27, 2022
Longer-term data show that the antisense oligonucleotide tofersen (Biogen) slows functional decline in patients with amyotrophic lateral sclerosis (ALS) caused by superoxide dismutase 1 (SOD1) gene […]
September 27, 2022
Contrary to findings from some previous studies, influenza vaccine does not increase the risk for Guillain-Barré syndrome (GBS), a large new study suggests. Investigators in Taiwan […]
September 26, 2022
Nightmares in healthy middle-aged and older adults may be an independent risk factor for cognitive decline and dementia, particularly in men, new research suggests. Results from […]
September 26, 2022
Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Not only has the prevalence of COVID-19 been high among patients with […]